The neuronal cytoskeleton as a potential target in the developmental neurotoxicity of organophosphorothionate insecticides.
Phosphorothionates are toxicologically the most important class of organophosphorus ester (OP) insecticides. Phosphorothionates are metabolically converted in vivo to their oxon analogues. These oxon metabolites can bind and inhibit acetylcholinesterase, thus causing acute cholinergic neurotoxicity. Oxon binding to the same target may also be partly responsible for manifestation of the 'intermediate syndrome'. More recent evidence suggests that the oxons may be also capable of inducing developmental neurotoxicity. The neuronal cytoskeleton may represent a potential target for the developmental neurotoxicity of the oxons because of its vital importance in many stages of normal neurodevelopment. Data obtained in the last five years and critically reviewed here indicate that the oxon metabolites, at concentrations that can be attained in vivo, exert potent effects on the neuronal cytoskeleton disrupting all three cytoskeletal networks. This disruption is expressed at the level of cytoskeletal protein expression, intracellular distribution, post-translational modification, cytoskeletal dynamics and function and may involve effects on both neuronal and glial cells. These effects are not secondary to other changes but may constitute primary effects of the oxons, as these compounds have been shown to be capable of covalently binding to and organophosphorylating multiple sites on tubulin and actin. Analogous studies must be extended to include other neurodevelopmentally important cytoskeletal proteins, such as neurofilament heavy chain, and tau, which are known to contain unusually high numbers of phosphorylatable sites and to establish whether organophosphorylation by the oxons takes place at sites where neurodevelopmentally relevant, endogenous, reversible phosphorylation is known to occur.
School of Veterinary Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
John
J
Flaskos
D000818:Animals; D002800:Cholinesterase Inhibitors / Q000378:metabolism / Q000633:toxicity; D003599:Cytoskeleton / Q000187:drug effects / Q000473:pathology; D006801:Humans; D007306:Insecticides / Q000378:metabolism / Q000633:toxicity*; D009474:Neurons / Q000166:cytology / Q000187:drug effects; D020258:Neurotoxicity Syndromes / Q000209:etiology* / Q000503:physiopathology; D063086:Organothiophosphates / Q000378:metabolism / Q000633:toxicity*; D010766:Phosphorylation / Q000187:drug effects
D002800:Cholinesterase Inhibitors; D007306:Insecticides; D063086:Organothiophosphates